Measuring the effectiveness of inhaled corticosteroids for COPD is not easy!

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 1, 2003, Pages 1-2

  Samet, Jonathan M ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ANTIINFLAMMATORY AGENT; STEROID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HOSPITALIZATION; HUMAN; MEASUREMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; CANADA; COHORT ANALYSIS; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; MORTALITY; NOTE; OBSERVATION; STANDARD; STATISTICAL ANALYSIS; STATISTICS;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HOSPITALIZATION; HUMANS; OBSERVATION; ONTARIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; SASKATCHEWAN; STEROIDS; TREATMENT OUTCOME;

EID: 0042805262     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2304004     Document Type: Editorial

References (14)

1. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
2. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-584.
3. Sin DD, Man SFP, Tu JV. Letter in response to "Effectiveness of inhaled corticosteroids in COPD: bias in observational studies." Am J Respir Crit Care Med (In press)
4. US Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force, 2nd ed. Baltimore, MD: Williams & Wilkins; 1996.
5. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999;149:981-983.
6. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
7. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-1503.
8. Munoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000;14:754-756.
9. Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, Munoz A. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001;154:675-681.
10. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
12. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-368.
13. Grady D. Postmenopausal hormones: therapy for symptoms only. N Engl J Med 2003;348:19-21.
14. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.